TCIM
JAZZ icon

TIAA CREF Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

TIAA CREF Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$220M Buy
1,539,767
+184,878
+14% +$24.1M 0.16% 131
2018
Q4 		$168M Buy
1,354,889
+22,717
+2% +$3.37M 0.13% 153
2018
Q3 		$224M Buy
1,332,172
+15,607
+1% +$2.68M 0.15% 147
2018
Q2 		$227M Buy
1,316,565
+75,113
+6% +$12.3M 0.15% 146
2018
Q1 		$187M Buy
1,241,452
+259,422
+26% +$38.1M 0.13% 169
2017
Q4 		$132M Sell
982,030
-72,301
-7% -$10M 0.09% 240
2017
Q3 		$154M Buy
1,054,331
+353,101
+50% +$53.4M 0.11% 207
2017
Q2 		$109M Buy
701,230
+37,682
+6% +$5.76M 0.08% 267
2017
Q1 		$96.3M Buy
663,548
+425,042
+178% +$55.4M 0.07% 298
2016
Q4 		$26M Buy
238,506
+57,609
+32% +$6.42M 0.02% 658
2016
Q3 		$22K Sell
180,897
-24,805
-12% -$3.34M 0.01% 736
2016
Q2 		$29.1M Sell
205,702
-138,441
-40% -$20.4M 0.02% 593
2016
Q1 		$44.9M Sell
344,143
-132,608
-28% -$16.5M 0.03% 464
2015
Q4 		$67M Sell
476,751
-14,922
-3% -$2.07M 0.05% 363
2015
Q3 		$65.3M Sell
491,673
-443
-0.1% -$76.3K 0.05% 364
2015
Q2 		$86.6M Sell
492,116
-20,120
-4% -$3.61M 0.06% 322
2015
Q1 		$88.5M Sell
512,236
-11,681
-2% -$2M 0.06% 335
2014
Q4 		$85.8M Buy
523,917
+89,690
+21% +$14.9M 0.06% 342
2014
Q3 		$69.7M Buy
434,227
+245
+0.1% +$37.7K 0.05% 381
2014
Q2 		$63.8M Sell
433,982
-269,595
-38% -$37.4M 0.04% 413
2014
Q1 		$97.6M Sell
703,577
-262,799
-27% -$39.6M 0.07% 314
2013
Q4 		$122M Buy
966,376
+7,223
+0.8% +$747K 0.09% 253
2013
Q3 		$88.2M Buy
959,153
+222,873
+30% +$18M 0.07% 305
2013
Q2 		$50.6M Buy
+736,280
New +$45M 0.04% 446

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

TIAA CREF Investment Management's JAZZ Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Jazz Pharmaceuticals (JAZZ) stake by 14% in Q1 2019, buying an estimated $24.1M and bringing the position to 1,539,767 shares worth $220M. The position accounts for 0.16% of the portfolio, ranked #131.

TIAA CREF Investment Management first reported a position in JAZZ in Q2 2013 and has held it in 24 quarters since. The position peaked at $227M in Q2 2018. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

  • TIAA CREF Investment Management held 1,539,767 shares of Jazz Pharmaceuticals worth $220M as of Q1 2019.
  • TIAA CREF Investment Management bought 184,878 Jazz Pharmaceuticals shares in Q1 2019, an estimated $24.1M.
  • Jazz Pharmaceuticals made up 0.16% of TIAA CREF Investment Management's portfolio in Q1 2019, its #131 holding.
  • TIAA CREF Investment Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Jazz Pharmaceuticals position peaked at $227M in Q2 2018.
  • 427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.